Theresa Tse

Softhale NV engages in manufacturing medical, clinical and pharmaceutical equipment. The company was founded by Jurgen Rawert and Frank Bartels and is headquartered in Diepenbeek, Belgium.

Pharmathen was founded in 1969 in Athens, as a private pharmaceutical company, and is focused on the development and marketing of pharmaceuticals, with a strong position in generics. With 3 state of the art research laboratories and 2 manufacturing units, Pharmathen is a completely vertically integrated company and its activities extend from the development of pharmaceutical products up to their distribution. The company's human resources works in the sectors of Research & Development (R&D), production and distribution of drugs to different countries worldwide. Now, Pharmathen's products are approved in all EU markets and distribution rights have been granted to the largest pharmaceutical companies in the world, particularly in Europe, the United States of America and Canada.

Beijing Tide Pharmaceutical Co., Ltd. engages in research, development, manufacturing and sale of pharmaceutical products. The firm's products include kaifen flurbiprofen axetil injection, kaishi alprostadil injection, kaina beraprost sodium tablet and deyou pronase granules. The company was founded in May 1995 and is headquartered in Beijing, China.

Treadwell Therapeutics, Inc. operates as a clinical-stage oncology firm. It develops small molecules designed to leverage world-class, innovative science in cancer biology and immune-oncology with pan-cancer potential, including hematological malignancies from the TIO Discovery development engine. The company was founded by Tak Wah Mak and Mark R. Bray in July 2019 and is headquartered in New York, NY.

France Investment (China 1) Group Ltd. operates as an investment holding company. The company is headquartered in Hongkong.

Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The company was founded in 1969, and the CEO is Kang Xin Yu.

Sino Biopharmaceutical (Beijing) Ltd. is an investment holding company. Its sole asset is its 33.6% interest in Beijing Tide Pharmaceutical Co., Ltd., a pharmaceutical company established in China with limited liability, which develops, manufactures, and market pharmaceutical products. Sino Biopharmaceutical (Beijing) was founded on December 31, 2007 and is headquartered in Hong Kong.

Pharmathen SA develops, manufactures, and markets pharmaceuticals. Its products include a-cnotren, adicanil, alcinin, atostana, aurid, azapin, belifax, calci-10, deprevix cr, esmocard, farbovil, faxiven, depilonine pro, depilonine cream, aripiprazole, atorvastatin, brinzolamide, caspofungin, and clopidogrel. The company was founded in 1969 and is headquartered in Pallini, Greece.

Part of Novartis AG, Sandoz AG is a Swiss company that develops generic medicines and biosimilars. The company is based in Basel, Switzerland.

PHion Therapeutics Ltd. operates as a therapeutic vaccine development company. Its vaccine program focuses on viral infections as it evokes a strong interferon gamma response. The firm's technology are RAVA and RAVA-V. The company was founded by Helen McCarthy in 2017 and is headquartered in Belfast, the United Kingdom.

Part of Deutsche Bank AG, Deutsche Bank AG (Hong Kong) is a financial institution that has been connecting worlds for 65 years. The company is based in Hong Kong, Hong Kong, and serves as the hub for corporate and commercial clients. The company's asset management division, DWS, is a market leader in Hong Kong with a broad product offering. Its corporate bank division is an established market leader in transaction banking, with a presence in 60 countries, including an extensive footprint in HK. The investment bank provides strategic advice to corporate and institutional clients, focusing on the bank’s traditional strengths in financing, advisory, fixed income, and currencies, together with a focused equity capital markets business. The private bank focuses on private customers across all segments as well as business clients, and in HK, this division is represented by a highly competitive wealth manager. The Chinese company was founded in 1958, and its CEO is Werner Steinmüller.